The present invention encompasses compounds of general formula (1)
wherein
R
1
to R
3
are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
本发明涵盖了一般式(1)的化合物
其中
R
1
至 R
3
如权利要求书中所定义,适用于治疗以细胞过度或异常增殖为特征的疾病,并用于制备具有上述特性的药物组合物。
New compounds
申请人:Zahn Stephan Karl
公开号:US20090163467A1
公开(公告)日:2009-06-25
The present invention encompasses compounds of general formula (1)
wherein
R
1
, R
2
, R
4
, X, m, n and p are defined as in claim
1
, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
本发明涵盖了一般式(1)的化合物
其中
R
1
,R
2
,R
4
,X,m,n和p的定义如权利要求书中所述
,适用于治疗以细胞过度或异常增殖为特征的疾病,并且用于制备具有上述特性的药物组合物。
Compounds
申请人:Zahn Stephan Karl
公开号:US20100144706A1
公开(公告)日:2010-06-10
The present invention encompasses compounds of general formula (1) wherein R
1
to R
4
, X and n are defined as in claim
1
, which are suitable for the treatment of ailments characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
The present invention encompasses compounds of general formula (1)
wherein
R
1
to R
3
are defined as in claim
1,
which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
2,4-Diaminopyrimidine als Inhibitoren von Zellzykluskinasen
申请人:Boehringer Ingelheim International GmbH
公开号:EP2357181A1
公开(公告)日:2011-08-17
Die vorliegende Erfindung umfasst Verbindungen der allgemeinen Formel (1)
worin
R1, R2, R4, Rg, X, m, n und p wie in Anspruch 1 definiert sind, welche zur Behandlung von Krankheiten, die durch exzessive oder anomale Zellproliferation charakterisiert sind, geeignet sind, sowie deren Verwendung zur Herstellung eines Arzneimittels mit den vorstehend genannten Eigenschaften.
本发明包括通式(1)的化合物
其中
R1、R2、R4、Rg、X、m、n 和 p 如权利要求 1 所定义,适用于治疗以细胞过度增殖或异常增殖为特征的疾病,并可用于制造具有上述性质的药物。